Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
SL VAXiGEN
SL VAXiGEN
NGM Biopharmaceuticals, Inc
Wellmarker Bio
R-Pharm
National Cancer Centre, Singapore
BJ Bioscience, Inc.
Anwita Biosciences
Biocad
Valley Health System
University of Louisville
Silverback Therapeutics
NSABP Foundation Inc
Curegenix Inc.
Monopteros Therapeutics Inc.
Shanghai Zhongshan Hospital
Olivia Newton-John Cancer Research Institute
Harbour BioMed (Guangzhou) Co. Ltd.
Lycera Corp.